

**Annex related to the Art. 127a**

**Conditions or restrictions with regard to the safe and effective use of the medicinal product to be implemented by the Member States**

## **Conditions or restrictions with regard to the safe and effective use of the medicinal product to be implemented by the Member States**

The Member States should ensure that all conditions or restrictions with regard to the safe and effective use of the medicinal product described below are implemented:

1. The Member State shall agree the details of the Prescriber kit and a controlled distribution system with the Marketing Authorisation Holder (MAH) and must implement such programme nationally prior to launch to ensure that:
  - Prior to prescribing (where appropriate, and in agreement with the National Competent Authority, dispensing) all healthcare professionals who intend to prescribe (and dispense) are provided with a prescriber kit containing the following:
    - Educational Health Care Professional's kit
    - Educational brochures for Patients
    - Patient cards
    - Summary of Product Characteristics (SmPC) and Package Leaflet and Labelling.